Sonnet BioTherapeutics Holdings, Inc.

Develops targeted cytokine therapies for cancer using a proprietary albumin-binding platform.

SONN | US

Overview

Corporate Details

ISIN(s):: US83548R1059
LEI:
Country:: United States of America
Address:: 100 OVERLOOK CENTER, 8540 PRINCETON
Website:: https://www.sonnetbio.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company that develops targeted biologic medicines. The company's core technology is its proprietary Fully Human Albumin-Binding (FHAB™) platform, which utilizes a single-chain antibody fragment (scFv) that binds to the body's own albumin. This 'hitch-hiking' mechanism is designed to deliver cytokine payloads directly to tumor tissues, enhancing drug penetration, retention, and local activation. Sonnet's therapeutic goal is to convert immunologically 'cold' tumors into 'hot' tumors, thereby making them more responsive to treatment. The company's pipeline consists of several cytokine-derived therapeutic candidates in clinical development.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Sonnet BioTherapeutics Holdings, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Sonnet BioTherapeutics Holdings, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Sonnet BioTherapeutics Holdings, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Cellbion Co., Ltd Develops & manufactures radiopharmaceuticals for cancer diagnosis and therapy.	South Korea	308430
CELL BIOTECH CO ., LTD A global biotech firm offering probiotic raw materials, OEM/ODM services, and consumer brands.	South Korea	049960
Celldex Therapeutics, Inc. Develops antibody-based therapies for severe inflammatory, allergic, and autoimmune diseases.	United States of America	CLDX
Cellectar Biosciences, Inc. Late-stage biopharma developing targeted cancer therapies with a proprietary PDC delivery platform.	United States of America	CLRB
Cellectis Develops 'off-the-shelf' CAR T-cell cancer immunotherapies using TALEN® gene-editing.	France	ALCLS
Cellid Co., Ltd. Biotech firm developing proprietary vaccine platforms for cancer and infectious diseases.	South Korea	299660
Cellromax Science Co., Ltd. Develops health foods, derma-cosmetics, and OTC drugs for pharmacies and online channels.	South Korea	471820
CellSeed Inc. Develops cell sheet products, culture equipment, and offers contract manufacturing services.	Japan	7776
CellSource Co.,Ltd. Processes patient-derived stem cells and PRP for regenerative therapies at medical facilities.	Japan	4880
Celltrion, Inc. A biopharma pioneer developing biosimilars and novel drugs for immunology and oncology.	South Korea	068270